Aurora Cannabis Inc (NYSE: ACB) shares bounced back Wednesday after a mixed fiscal third-quarter earnings report. One Wall Street analyst said Aurora is making progress on its long-term goals, but the company may also be dropping the ball on some valuable opportunities.
The Analyst
Bank of America analyst Christopher Carey reiterated his Buy rating and C$15 price target ($11 USD).
The Thesis
Carey said Aurora’s third-quarter results were a bit soft compared to his expectations, but investors should expect the company’s numbers to be volatile on a quarter-by-quarter basis in the near term. The most important takeaway from the quarter is Aurora reiterated its fourth-quarter guidance for 25,000 kg of cannabis ready for sale, positive EBITDA and improving margins heading into fiscal 2020.
Carey said Aurora is adding value by expanding into established products such as vapes and edibles, it might be missing out in another area.
“We see the strategy as reasonable; however, with so many companies also focused on these areas, and very few with the scale or capabilities to build advantages in untapped areas like beverages (with the exception of Canopy and Hexo), we wonder if Aurora could be ‘missing the boat’ on an area which could prove large as newer consumers wanting less pervasive, socially accepted product forms demand both psychoactive (THC-infused) and CBD beverages,†Carey wrote in a note.
Carey is bullish on Aurora, Canopy Growth Corp (NYSE: CGC) and Hexo Corp (NYSE: HEXO), but recently named Hexo his top cannabis stock pick. Aurora is the only one of the three that hasn’t announced a major partnership with a large consumer company, an announcement that could serve as a bullish near-term catalyst for the stock.
Price Action
Aurora's stock traded around $8.73 per share at time of publication.
Related Links:
Options Trader Makes 9K Bearish Bet On Aurora Cannabis Ahead Of Earnings
Bank Of America Initiates Coverage On Cannabis Stocks, Names Surprising Top Pick
Latest Ratings for ACB
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 2019 | Initiates Coverage On | Buy | ||
| Apr 2019 | Initiates Coverage On | Buy | ||
| Mar 2019 | Initiates Coverage On | Outperform |
View More Analyst Ratings for ACB
View the Latest Analyst Ratings
See more from Benzinga
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.